Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 519 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Combination of Immunotherapy Drugs Approved for Metastatic Colorectal Cancer August 3, 2018 Fatiga relacionada con el cáncer: Lo que las personas con cáncer... March 2, 2021 Deaths from Metastatic Melanoma Drop Substantially in the United States April 21, 2020 Mother and Daughter Graduate Nursing Masters Programs Together After Breast Cancer... May 8, 2020 Load more HOT NEWS Researchers Find a Way to Prevent Cancer Cells from Taking in... FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC Longitudinal Profiling of the Gut Microbiome in Patients Undergoing Immune Checkpoint... Experts Think Medical Detection Dogs Could Be Trained To Sniff Out...
